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THERE iS considerable evidence that the
progressive growth of solid tumours is
dependent on their ability to induce the
growth of new blood vessels from their
host, (Folkman, 1978; Gullino, 1978).
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Original work by Folkman et al. (1971)
indicated that such neovascularization was
induced by a humoral mediator secreted
by the tumour, which they called tumour
angiogenesis factor (TAF). They reported
-1rIG. I. tA) 1;llRc' eiorioauianitoic membrane, (UArNI) slowing a strong neovascular response to
purified TAF. The bloo(d vessels can be seen to proliferate in a "spoke-whlieel" pattern con-erging
tox%vards the souirce of TAFI'. (B) A control CAMI treated with lactose alone. For thlis assay fertilized
chicken eggs arc iincuibated in a humi(lified incubator at :373C. After wiping with beta(line, a small
lhole is (lrille(l in the shell of 3-day-old eggs an(l -1 ml of albumin is aspirated witlh a 19-gauge
needlle. Tlhe next day a rectangular win(low (1 x 2 5 cm) is cut along the hiorizontal axis of tlhe egg
an(t the shell anid slhell membrane are removcd. The wvindow is seale(l with sellotape, and the eggs
ieturned to the incubator. On the 10th (lay a flat rectangular glass marker is placed on the
clorioallaintoic mcmbrane. A small lhole is; madle in the membrane + 1 cm to the riglht of the
marker with a :30-gauge dlental nee(lle. Purified TAF in freeze-clried pow(der form witlh lactose as a
filler is placed( ovcr the lhole. The powder quickly dissolves and the window is resealed. The
chot-ioallanitois is examinied for niew- blood-x-vessel growtl (laily for 4 days.
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an active component which contained 25%
RNA, 10% protein and 50%0 carbo-
hydrate, the remainder probably being
lipid. Subsequently Folkman and his co-
workers purified a non-histone protein
from tumour-cell nuclei which was also
capable of inducing neovascularization in
vivo (Tuan et al., 1973).
Using the tumour extraction method
proposed by Folkman et al. but modified
to omit the trypsin step and introducing
an antibody raised against crude TAF
(Phillips & Kumar, 1979) we have isolated
a very low molecular weight (- 200) non-
protein component from rat Walker
tumours. This component is highly active
and capable of inducing angiogenesis in
E206
the chick chorioallantoic membrane (CAM)
assay in pg quantities (Fig. lI). It is also
capable of stimulating growth of endo-
thelial cells in culture (Schor etal., unpub.).
Crude TAF (mol. wt , 105) resulting
from gel filtration on Sephadex G100 of
the treated tissue homogenate was freeze-
dried and served as starting material for
the subsequent purification. The first step
was the separation of protein components
by chromatography on DEAE cellulose
using a convex salt gradient between 0
and 0-3m NaCl. At the end of the gradient
the column was further washed with 0-5M
NaCl. Activity could generally be detected
in one or two of the eluted peaks, but the
eluting positions of active material varied
in different batches of TAF. Fig. 2 gives
the position of the active peaks in 5
batches of TAF tested. All fractions from
the DEAE column were applied individu-
ally to an affinity-chromatography column
prepared by coupling absorbed TAF anti-
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FIG. 2. DEAE cellulose (hromatograplhy of
TAF extracts. A coluimn (4 x 1 cm) is
equilibrated with 50mm Tris/HCl buffer
(pH 7-3) at a flow rate of 85 ml/h, and
eluted with the same buffer containing a
convex salt gradlient of 0-0-3-i NaCl in a
total volume of 165 ml. The crtude TAF
(5-20 mg) is (lissolved in 5 ml starting
buffer immediately before application to the
column. 2ml fractions are collected. Tile
effluent is monitored by measuring extinc-
tion at 206 nm. Active peaks are indicated
by lhatching. Thte position of active peaks
varies between dlifferent batchles of crtu(le
TAF. The diagram slhows the elution pro-
files from 5 separate batches. A freslh
column was poured for each batchl.
Chlromatography was per-forme(d at 4°C.
FIa. 3. TAF antibody affinity columin: 5 mg
i5 mls of absorbed TAF antiserum is boun(d to 1 g
CNBr-activ-ate(d sephaiose (Pharmacia Ltd)
and the gel equilibrated with 50mm Tris-
HCI (pH 7 4) containing 0-5m NaCI. The
sample, normally about 20 ml of eluate
from the DEAE cellulose coltumn is
ptumpe(l on to the affinity column (1 x 3 cm)
at a flow rate of 50 ml/l. The coluimn is iun
at 4 C. 2ml fiactions are collected and the
coluimn monitored continuously at, 254 nm.
The column is tieni wxashed with thie
equilibrating buffer until a steady base line
is reaclle(l. Bouind material is elute(d with
50mM ammonium acetate (pH 3-7). The
activity of the elute(d material is tested on
CAMI assay after freeze (irying in tlhe
presence of 10 mg of lactose as filler. Pro-
(luction ancl characterizatioin of TAF-
antiserum hlas recently been (lescribedl
(Phillips & Kumar, 1979).
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body to CNBr Sepharose by conventional
methods. The bound material was eluted
with 50mM ammonium acetate buffer
(pH 3.7) and, after freeze drying to re-
move the volatile ammonium acetate
buffer, it was tested for activity using the
CAM assay system. Detection ofthe bound
material by conventional UV detectors
was difficult, as only a small "blip" on
the E254 absorbance line could be seen
(Fig. 3). A small "blip" was present even
when no activity could be detected by
biological test. The active peaks in
Fig. 2 correspond to those peaks which
gave a positive CAM result for absorbed
material on TAF antibody-affinity
chromatography. The experiments de-
scribed have been repeated on more than
9 different batches of crude TAF and
identical results obtained. The pattern of
protein peaks obtained on DEAE cellulose
chromatography differed from batch to
batch. This probably reflects differences in
exposure time to neutral proteinases
Arhich we have detected in the crude mix-
tures. The variable position ofTAF bouind
to these protein fractions is interesting. It
seems likely that they are acting as non-
specific carriers of TAF. In order to check
whether a charge difference occurred in
the protein carrier peak after removal of
the active material, the unbound protein
peakfromtheaffinitycolumn was dialysed,
concentrated and reapplied to a DEAE
cellulose column. The peak emerged in a
position identical to its previous one. This
suggests that the charge contribution of
TAF to the overall charge of the protein
carrier is not significant.
On dialysis in ammonium acetate (pH
3.7) the bound material from an affinity-
chromatography column equilibrated
within 30 min and the material outside the
bag was highly active. Since this suggested
that the active component was of low
molecular weight we applied the bound
fraction from an affinity column to a
Biogel P2 column (excluLsion limit 2500
mol. wt) with 10% isopropanol in water as
packing and eluting solvent. An active
peak emerged from the included portion
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FIG. 4. Elution profile on Biogel P2 (45 x 4-4
cm) column of activxe TAF fraction elute(d
from affinity-chromatography column (Fig.
3). The column effluent was monitored by
measuring the extinction at 206 nm. The
material was applied in a total xolume of
5-15 ml. The activre peak is marked with an
arrow. Gel filtration was by upwTard flow in
10% isopropanol water (20 ml/h) at 4°C.
Chlromatographically pure isopropanol
(BDH Ltd) was used in all experiments.
The eltution position of known amino aciel
and peptide markers is shown. The activle
material can be seen to elute at a mol. w t
')osition of 200. The majority of the inaterial in this area is non-specific im-
purity, as shown by controls.
of the column at a volume which corre-
sponded to a mol. wt of -200 (Fig. 4).
(This figure must be an approximation
since in this system we do not find a
straight-line relationship between all
marker molecules ofknown mol. wt below
500, although the amount of variation
from linearity is not great). The active
peak was followed by 2 much larger but
lower mol.-wt peaks which were inactive.
The rapid equilibration of the material
between the retentate and dialysate and
the position of its elution on Biogel P2
indicate a very low mol. wt. The chemical
nature of the small molecule, which we
believe to be the true tumour angiogenic
factor, is currently being investigated. It
is not a prostaglandin, a protein or a pep-
tide and neither is it a nucleic acid. We are
also interested in the carrier molecules in-
volved, as these may be either artifacts of
preparation or natural binding carriers
which are needed for transport of the
molecule in vivo.
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It may be of interest that neither our
purified TAF nor an angiogenic factor
which we have detected in synovium from
an actively inflamed ankylosing spondy-
litic joint (results to be published) gives a
precipitin line against TAF antibody.
This may be due to the small size of the
angiogenic factor(s). Human kidney
tumours, which are the only human
tumours we have so far investigated, do
share common antigenic determinants
with rat TAF (Phillips & Kumar, 1979).
It is likely that angiogenic factor or fac-
tors are not unique to tumour cells, but
that there is an excess production of them
in the malignant cell. We feel that once
the chemical nature of the angiogenic
factor is established, it mav have both
prophylactic and diagnostic implications
in huiman mnalignant disease, or in other
conditions wvhere angiogenesis is a feature.
This work was partly finanled(1 by a grant to
J.B.T. from the Arthritis andl Rheumatism Council,
ancl by a grant to S.K. from the C:ancer Research
Campaign.
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